Panel Calls on FDA to Review Safety of Opoiod Painkillers

July 17, 2017

(ABC News) – The U.S. Food and Drug Administration should review the safety and effectiveness of all opioids, and consider the real-world impacts the powerful painkillers have, not only on patients, but also on families, crime and the demand for heroin. That’s the conclusion of a sweeping report Thursday from the National Academies of Sciences, Engineering and Medicine. It urges the FDA to bolster a public health approach that already has resulted in one painkiller being pulled from the market. Last week, the maker of opioid painkiller Opana ER withdrew its drug at the FDA’s request following a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles to inject the pills.

Recommended Reading